AMENDMENTS TO THE CLAIMS

Please amend the claims as follows, without prejudice or disclaimer.

Claim 1 (previously and currently amended) A method for inducing an immune response to a tumor antigen in an animal comprising a priming step wherein a tumor antigen is administered in a first form into a lymphatic site ~~in~~ of an animal and a boosting step wherein the tumor antigen is administered in a second form into a lymphatic site of the animal, where the form of the tumor antigen administered in the priming and boosting steps are different and at least one of said forms is administered into a lymph node.

Claim 2 (Currently amended) A method according to claim 1 wherein the tumor antigen is selected from the group consisting of CEA, gp100, the MAGE family of proteins, DAGE, GAGE, RAGE, NY-ESO 1, Melan-A/MART 1, TRP-1, TRP-2, tyrosinase, HER-2/neu, MUC-1, p53, KSA, PSA, PSMA, ~~and~~ fragments thereof and modified versions thereof.

Claim 3 (Cancelled)

Claim 4 (Currently amended) A method according to claim 1 wherein ~~the viral nucleic acid is~~ at least one of said forms is a nucleic acid encoding the tumor antigen and the nucleic acid is selected from the group consisting of viral nucleic acid, bacterial DNA, plasmid DNA, naked~~/free~~ DNA, and RNA.

Claim 5 (Original) A method according to claim 4 wherein the viral nucleic acid is selected from the group consisting of adenoviral, alphaviral and poxviral nucleic acid.

Claim 6 (Original) A method according to claim 5 wherein the poxviral nucleic acid selected from the group consisting of avipox, orthopox and suipox nucleic acid.

Claim 7 (Original) A method according to claim 5 wherein the poxviral nucleic acid is selected from the group consisting of vaccinia, fowl pox, canarypox and swinepox nucleic acid.

Claim 8 (Original) A method according to claim 5 wherein the poxviral nucleic acid is selected from the group consisting of MVA, NYVAC, TROVAC, and ALVAC nucleic acid.

Claim 9 (Currently amended) A method according to claim 1 wherein ~~the~~ at least one of said forms is a nucleic acid encoding the tumor antigen and the nucleic acid is contained in a vector.

Claim 10 (Original) A method according to claim 9 wherein the vector is a recombinant virus or bacteria.

Claim 11 (Original) A method according to claim 10 wherein the recombinant virus is selected from the group consisting of adenovirus, alphavirus and poxvirus.

Claim 12 (Original) A method according to claim 11 wherein the poxvirus is selected from the group consisting of avipox, orthopox and suipox.

Claim 13 (Original) A method according to claim 11 wherein the poxvirus is selected from the group consisting of vaccinia, fowlpox, canarypox and swinepox.

Claim 14 (Original) A method according to claim 11 wherein the poxvirus is selected from the group consisting of MVA, NYVAC, TROVAC, and ALVAC.

Claim 15 (Currently amended) A method according to claim 1 wherein at least one of said forms is a nucleic acid encoding the tumor antigen and the nucleic acid is contained in a cell.

Claim 16 (Currently amended) A method according to claim 1 wherein at least one of said forms is a nucleic acid encoding the tumor antigen and the ~~tumor antigen of~~ nucleic acid ~~coding therefore~~ is contained in a ~~vaccine~~ a pharmaceutical composition.

Claim 17 (Currently amended) A method according to claim 1 wherein the tumor antigen is selected from the group consisting of gp100, carcinoembryonic antigen (CEA), ~~CEA or~~ a fragment of gp100, a fragment of CEA, a ~~or~~ modified version of gp100, and a ~~or~~modified version of CEA.

Claim 18 (Currently amended) A method according to claim 17 wherein the modified version of gp100 comprises at least the sequence IMDQVPFSY (SEQ ID NO: 1) ~~and/~~or the sequence YLEPGPVTV (SEQ ID NO:2).

Claim 19 (Currently amended) A method according to claim 17 wherein the modified version of CEA comprises at least the sequence shown in Figure 8 (SEQ ID NO:112) ~~and/~~or the sequence YLSGADLNL (SEQ ID NO:113).

Claim 20 (New) A method of claim 1 wherein both the first and second forms are administered into the lymph node.

Claim 21 (New) A method according to claim 1 wherein the first form is a nucleic acid and the second form is a peptide.

Claim 22 (New) A method according to claim 21 wherein the tumor antigen is selected from the group consisting of CEA, gp100, the MAGE family of proteins, DAGE, GAGE, RAGE, NY-ESO 1, Melan-A/MART 1, TRP-1, TRP-2, tyrosinase, HER-2/neu, MUC-1, p53, KSA, PSA, PSMA, fragments thereof, and modified versions thereof.

Claim 23 (New) A method according to claim 21 wherein the nucleic acid is selected from the group consisting of viral nucleic acid, bacterial DNA, plasmid DNA, naked DNA, and RNA.

Claim 24 (New) A method according to claim 23 wherein the viral nucleic acid is selected from the group consisting of adenoviral, alphaviral and poxviral nucleic acid.

Claim 25 (New) A method according to claim 24 wherein the poxviral nucleic acid selected from the group consisting of avipox, orthopox and suipox nucleic acid.

Claim 26 (New) A method according to claim 25 wherein the poxviral nucleic acid is selected from the group consisting of vaccinia, fowl pox, canarypox and swinepox nucleic acid.

Claim 27 (New) A method according to claim 26 wherein the poxviral nucleic acid is selected from the group consisting of MVA, NYVAC, TROVAC, and ALVAC nucleic acid.

Claim 28 (New) A method of claim 21 wherein both the first and second forms are administered into the lymph node.